Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of subcutaneous tocilizumab in giant cell arteritis (France, post-WA28119)
2016-002716-41Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in giant cell arteritis (GCA), sponsored by Roche. Primary endpoint: Incidence, nature, and severity of adverse events. Started Apr 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2016-002716-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002716-41.